Overview

Neoadjuvant Low-Dose Radiotherapy Plus Targeted-Immunotherapy vs Targeted-Immunotherapy Monotherapy in Resectable HNSCC: A Randomized Trial

Status:
RECRUITING

Trial end date:
2026-06-30

Target enrollment:

Participant gender:

Summary

This study compares the efficacy of neoadjuvant low-dose radiotherapy plus targeted-immunotherapy versus targeted-immunotherapy alone in resectable HNSCC patients.

Phase:

PHASE2

Details

Lead Sponsor:

West China Hospital

Treatments:

Afatinib
Immunotherapy
Radiotherapy
tislelizumab